Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH: Docetaxel vs Cabazitaxel in mCRPC
NCT01576029Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2012
- Primary completion
- Dec 2013
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Sanofi. Primary endpoint: Time to PSA Progression up to 60 days. Started Aug 2012; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01576029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01576029.